NH160030

Primary objective: To evaluate the safety and tolerability of NH160030 tablets of different doses taken orally on an empty stomach in patients with non-cancer chronic pain. Secondary objective: To evaluate the pharmacokinetic (PK) characteristics of NH160030 tablets of different doses taken orally on an empty stomach in patients with non-cancer chronic pain; to identify the in vivo metabolites of NH160030 tablets and detect their abundance. To evaluate the effect of food on the pharmacokinetics of NH160030 tablets after a single dose. Exploratory objective: If the data is sufficient and feasible, preliminarily explore and evaluate the pharmacodynamic (PD) characteristics of NH160030 tablets of different doses taken orally on an empty stomach in patients with non-cancer chronic pain, and preliminarily explore the relationship between dose-exposure-effect. The above studies are not necessary for clinical reports.